Vigil Neuroscience, Inc. (VIGL) |
|
10.94 0.29 (2.72%)
|
02-02 15:21 |
|
Open: |
10.7 |
Pre. Close: |
10.65 |
|
High:
|
11.0209 |
Low:
|
10.55 |
|
Volume:
|
4,659 |
Market Cap:
|
389(M) |
|
|
|
Technical analysis |
as of: 2023-02-02 3:15:51 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 13.92 One year: 15.13 |
| Support: |
Support1: 10.23 Support2: 8.51 |
| Resistance: |
Resistance1: 11.92 Resistance2: 12.96 |
| Pivot: |
11.31  |
| Moving Average: |
MA(5): 10.82 MA(20): 11.49
MA(100): 11.59  MA(250): 8.86 |
| MACD: |
MACD(12,26): -0.4 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 12.8 %D(3): 15.5 |
| RSI: |
RSI(14): 42.3 |
| 52-week: |
High: 18.27 Low: 2.18 |
| Average Vol(K): |
3-Month: 36 (K) 10-Days: 13 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ VIGL ] has closed above bottom band by 27.6%. Bollinger Bands are 34.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
10.72 - 10.78 |
10.78 - 10.82 |
|
Low:
|
10.5 - 10.57 |
10.57 - 10.63 |
|
Close:
|
10.55 - 10.66 |
10.66 - 10.75 |
|
Company Description |
|
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts. |
Headline News |
Wed, 01 Feb 2023
Northpond Ventures, LLC's Top - GuruFocus.com
Wed, 25 Jan 2023
Is Vigil Neuroscience Inc (VIGL) a Bad Choice in Biotechnology Wednesday? - InvestorsObserver
Mon, 23 Jan 2023
Catalyst Pharmaceuticals, Xylem And Other Big Stocks Moving ... - Investing.com UK
Wed, 18 Jan 2023
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives Average Rating ... - MarketBeat
Tue, 29 Nov 2022
Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation - Simply Wall St
Mon, 28 Nov 2022
Watch This Alpinist Seek the Threshold of Commitment - GearJunkie
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
5 (M) |
|
% Held by Insiders
|
12.8 (%) |
|
% Held by Institutions
|
114.3 (%) |
|
Shares Short
|
293 (K) |
|
Shares Short P.Month
|
298 (K) |
Stock Financials |
|
EPS
|
0 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.77 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-61 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
